Cancer prevention and control: hepatocellular carcinoma

Liver cancer (mostly hepatocellular carcinoma, HCC) is both common and highly lethal throughout Africa, in particular in western and middle Africa where HCC is the first cause of cancer death in men and the third in women. In these high-incidence areas, HCC develops mostly early (<50 years), with an aggressive clinical course and frequently without prior diagnosis of liver cirrhosis. The dynamics of African populations predict that the burden of liver cancers will be multiplied by three to four in the next decades unless effective prevention and therapy is achieved. This article outlines a path for significantly curbing the mortality of liver cancer in Africa by combining primary prevention, improved early detection and introduction of innovative and appropriate management strategies.

[1]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[2]  M. Manns,et al.  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[4]  G. Gores,et al.  Liver cancer: Approaching a personalized care. , 2015, Journal of hepatology.

[5]  Claude B. Sirlin,et al.  LI‐RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI‐RADS Management Working Group and future directions , 2015, Hepatology.

[6]  A. Baccarelli,et al.  IARC Monographs: 40 Years of Evaluating Carcinogenic Hazards to Humans , 2015, Environmental health perspectives.

[7]  H. Reeves,et al.  The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[8]  Y. Hoshida,et al.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. , 2012, Current cancer drug targets.

[9]  A. Jemal,et al.  Cancer burden in Africa and opportunities for prevention , 2012, Cancer.

[10]  H. Whittle,et al.  Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[11]  H. El‐Serag,et al.  Utilization of Surveillance for Hepatocellular Carcinoma Among Hepatitis C Virus–Infected Veterans in the United States , 2011, Annals of Internal Medicine.

[12]  P. Boyle,et al.  Curbing the liver cancer epidemic in Africa , 2008, The Lancet.

[13]  J. Bruix,et al.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma , 2007, Hepatology.

[14]  R. Montesano,et al.  Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. , 2006, Carcinogenesis.

[15]  J. Otegbayo,et al.  Temporal and biological trends in liver cancers at a University hospital in Southwest Nigeria , 2006, Tropical doctor.

[16]  A. Hall,et al.  Liver cancer in low and middle income countries , 2003, BMJ : British Medical Journal.

[17]  T. Wright,et al.  The epidemiology and prevention of hepatocellular carcinoma. , 2001, Seminars in oncology.

[18]  P. Hainaut,et al.  Hepatocellular carcinoma: from gene to public health. , 1997, Journal of the National Cancer Institute.